HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 297 filers reported holding HAEMONETICS CORP in Q3 2023. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,649,634 | +4.9% | 386,806 | -0.3% | 0.01% | +10.0% |
| Q2 2023 | $33,037,641 | -13.3% | 388,039 | -15.7% | 0.01% | -16.7% |
| Q1 2023 | $38,085,026 | +8.6% | 460,242 | +3.2% | 0.01% | 0.0% |
| Q4 2022 | $35,071,000 | +4.5% | 445,876 | -1.6% | 0.01% | 0.0% |
| Q3 2022 | $33,551,000 | +29.3% | 453,198 | +13.8% | 0.01% | +33.3% |
| Q2 2022 | $25,946,000 | +136.4% | 398,077 | +129.3% | 0.01% | +200.0% |
| Q1 2022 | $10,974,000 | +189.2% | 173,585 | +142.5% | 0.00% | +200.0% |
| Q4 2021 | $3,795,000 | -27.3% | 71,570 | -3.2% | 0.00% | -50.0% |
| Q3 2021 | $5,222,000 | -28.9% | 73,974 | -32.9% | 0.00% | 0.0% |
| Q2 2021 | $7,344,000 | -91.2% | 110,190 | -85.4% | 0.00% | -92.9% |
| Q1 2021 | $83,860,000 | +7.1% | 755,424 | +14.6% | 0.03% | 0.0% |
| Q4 2020 | $78,308,000 | +84.8% | 659,418 | +35.8% | 0.03% | +64.7% |
| Q3 2020 | $42,379,000 | +12.4% | 485,732 | +15.4% | 0.02% | +6.2% |
| Q2 2020 | $37,704,000 | -2.9% | 420,986 | +8.0% | 0.02% | -20.0% |
| Q1 2020 | $38,840,000 | +198.1% | 389,732 | +243.7% | 0.02% | +300.0% |
| Q4 2019 | $13,029,000 | -18.6% | 113,392 | -10.7% | 0.01% | -28.6% |
| Q3 2019 | $16,009,000 | -4.6% | 126,911 | -9.0% | 0.01% | -12.5% |
| Q2 2019 | $16,778,000 | -48.3% | 139,427 | -62.4% | 0.01% | -46.7% |
| Q1 2019 | $32,470,000 | -25.5% | 371,159 | -14.8% | 0.02% | -31.8% |
| Q4 2018 | $43,563,000 | -10.8% | 435,411 | +2.2% | 0.02% | +29.4% |
| Q3 2018 | $48,826,000 | -17.0% | 426,147 | -35.0% | 0.02% | -34.6% |
| Q2 2018 | $58,806,000 | -34.9% | 655,774 | -46.9% | 0.03% | -36.6% |
| Q1 2018 | $90,284,000 | +179.9% | 1,233,989 | +122.2% | 0.04% | +173.3% |
| Q4 2017 | $32,257,000 | +24.2% | 555,329 | -4.0% | 0.02% | +25.0% |
| Q3 2017 | $25,969,000 | +13.7% | 578,717 | +0.0% | 0.01% | +9.1% |
| Q2 2017 | $22,844,000 | +18.4% | 578,516 | +21.6% | 0.01% | +10.0% |
| Q1 2017 | $19,292,000 | +43.2% | 475,566 | +41.9% | 0.01% | +42.9% |
| Q4 2016 | $13,469,000 | +9.8% | 335,066 | -1.1% | 0.01% | 0.0% |
| Q3 2016 | $12,266,000 | +33.7% | 338,777 | +7.1% | 0.01% | +40.0% |
| Q2 2016 | $9,173,000 | -10.2% | 316,311 | +8.3% | 0.01% | -16.7% |
| Q1 2016 | $10,217,000 | -38.5% | 292,066 | -43.3% | 0.01% | -40.0% |
| Q4 2015 | $16,601,000 | -18.1% | 514,917 | -17.9% | 0.01% | -23.1% |
| Q3 2015 | $20,259,000 | -42.7% | 626,819 | -26.6% | 0.01% | -35.0% |
| Q2 2015 | $35,334,000 | +0.2% | 854,404 | +8.8% | 0.02% | 0.0% |
| Q1 2015 | $35,273,000 | +26.1% | 785,226 | +5.0% | 0.02% | +25.0% |
| Q4 2014 | $27,982,000 | -8.0% | 747,756 | -14.1% | 0.02% | -11.1% |
| Q3 2014 | $30,402,000 | -7.3% | 870,652 | -6.3% | 0.02% | -5.3% |
| Q2 2014 | $32,797,000 | +6.6% | 929,587 | -1.5% | 0.02% | +5.6% |
| Q1 2014 | $30,753,000 | +38.3% | 943,589 | +78.8% | 0.02% | +38.5% |
| Q4 2013 | $22,229,000 | +42.4% | 527,647 | +34.8% | 0.01% | +30.0% |
| Q3 2013 | $15,607,000 | -3.0% | 391,368 | +0.6% | 0.01% | -9.1% |
| Q2 2013 | $16,092,000 | – | 389,187 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |